RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis

Tsantikidi,Aikaterini; Papazisis,Konstantinos; Floros,Theofanis; Gazouli,Maria; Papadopoulou,Eirini; Tsaousis,Georgios; Nasioulas,Georgios; Mester,Andra; Milan,Kubelac Paul; Gozman,Bogdan; Afrasanie,Vlad; Stanculeanu,Dana Lucia; Trifanescu,Oana; Pescaru,Florentina; Militaru,Claudia; Papadimitriou,Christos

doi:10.3892/ol.2023.14060

RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis

Authors:
- Aikaterini Tsantikidi
- Konstantinos Papazisis
- Theofanis Floros
- Maria Gazouli
- Eirini Papadopoulou
- Georgios Tsaousis
- Georgios Nasioulas
- Andra Mester
- Kubelac Paul Milan
- Bogdan Gozman
- Vlad Afrasanie
- Dana Lucia Stanculeanu
- Oana Trifanescu
- Florentina Pescaru
- Claudia Militaru
- Christos Papadimitriou
View Affiliations

Affiliations: Genekor Medical S.A., Gerakas, 15344 Athens, Greece, Department of Oncology, Euromedica General Clinic, 54645 Thessaloniki, Greece, Department of Oncology, Athens Naval and Veterans Hospital, 11521 Athens, Greece, Department of Basic Medical Sciences National, Kapodistrian University of Athens, 11527 Athens, Greece, Oncological Institute, 400015 Cluj‑Napoca, Romania, Regional Institute of Oncology, 700483 Iasi, Romania, Bucharest Oncological Institute, 700483 Bucuresti, Romania, St. Constantine Hospital, 500091 Brasov, Romania, Medisprof Cluj‑Napoca, 400641 Cluj‑Napoca, Romania, Second Department of Surgery, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11528, Greece
Published online on: September 22, 2023 https://doi.org/10.3892/ol.2023.14060
Article Number: 480
Copyright: © Tsantikidi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumors harboring homologous recombination deficiency (HRD) are considered optimal candidates for poly(ADP‑ribose) polymerase 1 (PARP) inhibitor treatment. Such deficiency can be detected by analyzing breast cancer type (BRCA)1/2 gene mutations, as well as mutations in other genes of the homologous recombination pathway. The algorithmic measurement of the HRD effect by identifying genomic instability (GI) has been used as biomarker. As compared with the direct measurement of somatic gene alterations, this approach increases the number of patients who could benefit from PARP inhibitor treatment. In the present study, the performance of the Oncoscan CNV assay, accompanied by appropriate bioinformatic algorithms, was evaluated for its performance in GI calculation and was compared with that of a validated next‑generation sequencing (NGS) test (myChoice HRD test). In addition, the clinical utility of the GI score (GIS) and BRCA1/2 tumor analysis were investigated in a cohort of 444 patients with ovarian cancer. For that reason, single nucleotide polymorphism (SNP) arrays and appropriate bioinformatics algorithms were used to calculate GIS in 29 patients with ovarian cancer with known GIS status using a validated NGS test. Furthermore, BRCA1/2 analysis results were compared between the aforementioned assay and the amplicon‑based Oncomine™ BRCA Research Assay. BRCA1/2 analysis was performed in 444 patients with ovarian cancer, while GIS was calculated in 175 BRCA1/2‑negative cases. The bioinformatics algorithm developed for GIS calculation in combination with NGS BRCA1/2 analysis (RediScore), and the OncoscanR pipeline exhibited a high overall agreement with the validated test (93.1%). In addition, the Oncomine NGS assay had a 100% agreement with the validated test. The BRCA1/2 mutation frequency was 26.5% in the examined patients with ovarian cancer. GIS was positive in 40% of the BRCA1/2‑negative cases. The RediScore bioinformatics algorithm developed for GIS calculation in combination with NGS BRCA1/2 analysis is a viable and effective approach for HRD calculation in patients with ovarian cancer, offering a positive prediction for PARP inhibitor responsiveness in 55% of the patients.

View Figures

View References

1	Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M and Cai X: Advances in synthetic lethality for cancer therapy: Cellular mechanism and clinical translation. J Hematol Oncol. 13:1182020. View Article : Google Scholar : PubMed/NCBI
2	Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, et al: Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 12:24872021. View Article : Google Scholar : PubMed/NCBI
3	Konstantinopoulos PA, Ceccaldi R, Shapiro GI and D'Andrea AD: Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5:1137–1154. 2015. View Article : Google Scholar : PubMed/NCBI
4	Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, et al: Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1/ENGOT-ov25 trial. JCO Precis Oncol. 7:e22002582023. View Article : Google Scholar : PubMed/NCBI
5	Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, et al: ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 31:1606–1622. 2020. View Article : Google Scholar : PubMed/NCBI
6	Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 381:2416–2428. 2019. View Article : Google Scholar : PubMed/NCBI
7	Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, Collins G, French T, Ghahramani N, Hinson P, et al: Homologous recombination deficiency: Concepts, definitions, and assays. Oncologist. 27:167–174. 2022. View Article : Google Scholar : PubMed/NCBI
8	O'Sullivan Coyne G, Karlovich C, Wilsker D, Voth AR, Parchment RE, Chen AP and Doroshow JH: PARP inhibitor applicability: Detailed assays for homologous recombination repair pathway components. Onco Targets Ther. 15:165–180. 2022. View Article : Google Scholar : PubMed/NCBI
9	Cristescu R, Liu XQ, Arreaza G, Chen C, Albright A, Qiu P and Marton MJ: Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test. BMC Cancer. 22:13102022. View Article : Google Scholar : PubMed/NCBI
10	Ngoi NYL and Tan DSP: The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open. 6:1001442021. View Article : Google Scholar : PubMed/NCBI
11	Foster JM, Oumie A, Togneri FS, Vasques FR, Hau D, Taylor M, Tinkler-Hundal E, Southward K, Medlow P, McGreeghan-Crosby K, et al: Cross-laboratory validation of the OncoScan^® FFPE assay, a multiplex tool for whole genome tumour profiling. BMC Med Genomics. 8:52015. View Article : Google Scholar : PubMed/NCBI
12	Rowe LR, Thaker HM, Opitz JM, Schiffman JD, Haddadin ZM, Erickson LK and South ST: Molecular inversion probe array for the genetic evaluation of stillbirth using formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 15:466–472. 2013. View Article : Google Scholar : PubMed/NCBI
13	Wang Y, Moorhead M, Karlin-Neumann G, Falkowski M, Chen C, Siddiqui F, Davis RW, Willis TD and Faham M: Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res. 33:e1832005. View Article : Google Scholar : PubMed/NCBI
14	Ross EM, Haase K, Van Loo P and Markowetz F: Allele-specific multi-sample copy number segmentation in ASCAT. Bioinformatics. 37:1909–1911. 2021. View Article : Google Scholar : PubMed/NCBI
15	Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, et al: Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA. 107:16910–16915. 2010. View Article : Google Scholar : PubMed/NCBI
16	Imanishi S, Naoi Y, Shimazu K, Shimoda M, Kagara N, Tanei T, Miyake T, Kim SJ and Noguchi S: Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. Breast Cancer Res Trea. 174:627–637. 2019. View Article : Google Scholar : PubMed/NCBI
17	Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, et al: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 107:1776–1782. 2012. View Article : Google Scholar : PubMed/NCBI
18	Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2:366–375. 2012. View Article : Google Scholar : PubMed/NCBI
19	Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72:5454–5462. 2012. View Article : Google Scholar : PubMed/NCBI
20	Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, et al: Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16:4752014. View Article : Google Scholar : PubMed/NCBI
21	Popova T, Manié E and Stern MH: Genomic signature of homologous recombination deficiency in breast and ovarian cancers. Bio-Protocol. 3:2013. View Article : Google Scholar
22	Christinat Y, Ho L, Clément S, Genestie C, Sehouli J, Gonzalez Martin A, Denison U, Fujiwara K, Vergote I, Tognon G, et al: Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma. medRxiv. 2022.08.22.22278669. 2022.
23	Wiggans AJ, Cass GKS, Bryant A, Lawrie TA and Morrison J: Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2015:CD0079292015.PubMed/NCBI
24	Konecny GE and Kristeleit RS: PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: Current practice and future directions. Br J Cancer. 115:1157–1173. 2016. View Article : Google Scholar : PubMed/NCBI
25	Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinieri S, Guerra Alía EM, Polterauer S, Yoshida H, et al: Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 181:42–52. 2023. View Article : Google Scholar : PubMed/NCBI
26	Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, et al: Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: Phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Ann Oncol. 34:152–162. 2023. View Article : Google Scholar : PubMed/NCBI
27	Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, et al: Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Re. 22:3764–3773. 2016. View Article : Google Scholar : PubMed/NCBI
28	Doig KD, Fellowes AP and Fox SB: Homologous recombination repair deficiency: An overview for pathologists. Mod Pathol. 36:1000492023. View Article : Google Scholar : PubMed/NCBI
29	Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, Vacirca D, Colombo N and Barberis M: In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: A feasibility study comparing AmoyDx HRD focus panel with myriad myChoiceCDx assay. Pathologica. 114:288–294. 2022. View Article : Google Scholar : PubMed/NCBI
30	Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, et al: Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: Associations with clinical outcome following platinum monotherapy. Mol Cancer Res. 16:1103–1111. 2018. View Article : Google Scholar : PubMed/NCBI